What are the opening hours?

Monday 9am - 5:30pm Tuesday 9am - 5:30pm Wednesday 9am - 5:30pm Thursday 9am - 5:30pm Friday 9am - 5:30pm

Primary Care Diabetes and Obesity Society

Home
United Kingdom
London
Primary Care Diabetes and Obesity Society

The PCDO Society champions clinical quality in diabetes, obesity and associated long-term conditions.

The information provided in these social media posts should not be used for diagnosis or treatment of any medical condition.

19/09/2025

New data that will help us with our discussions on diet. Do chips, boiled, mashed and baked potatoes confer different risks of developing type 2 diabetes?

https://eu1.hubs.ly/H0m_s3-0

18/09/2025

Representatives of the PCDO Society committee out in force at EASD 2025. Very grateful to be here in Vienna and looking forward to sharing our learning with you.
Chair regretfully banished from photo. 😆

18/09/2025

⏰ Final call! Secure your spot at the Northern Ireland PCDO Conference on 25 September. Join industry leaders, connect with peers, and boost your expertise—all while earning 5 CPD points. Don’t miss out—register today! https://eu1.hubs.ly/H0n9jM10

This conference was developed by the PCDO Society in conjunction with OmniaMed Communications. The sponsoring pharmaceutical, device, training and educational companies have contributed financial support towards this event but have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible. A full list of confirmed sponsors for this event can be found by clicking on this link. https://eu1.hubs.ly/H0n9h6y0

17/09/2025

Bringing you all the latest from the EASD annual meeting. Interviews, coverage and summaries coming up!

16/09/2025

Our latest interactive case study reviews the practicalities of prescribing incretin-based therapies for the management of type 2 diabetes.

Test your knowledge at: https://eu1.hubs.ly/H0m_q9_0

15/09/2025

PCDO Society Chair, Naresh Kanumilli, attended the European Society of Cardiology 2025 Congress in Madrid at the end of August, where he was able to sit down with three titans of research at the intersection of diabetes, cardiology and nephrology. Watch his interviews with Brendon Neuen, Javed Butler and Naveed Sattar, and hear their (at times controversial!) opinions on weight loss, type 2 diabetes prevention, SGLT2 inhibitors, GLP-1 receptor agonists, finerenone and aldosterone synthase inhibitors.

https://eu1.hubs.ly/H0n24Ch0

14/09/2025

Increased risk of new-onset heart failure in over-65s suggests caution is required before prescribing pregabalin for painful diabetic neuropathy.

Read more: https://eu1.hubs.ly/H0m_qgt0

12/09/2025

More data on incretin therapies and risk of retinopathy. Crucial that we review retinal screening reports prior to prescribing GLP-1 or GIP/GLP-1 receptor agonists:

https://eu1.hubs.ly/H0m_pYZ0

01/09/2025

Join Professor Kate O'Donnell at the 21st National Conference of the PCDO Society to learn all about missingness, and what we can do to help, including:

The consequences of missing data
Managing harder-to-reach populations
Increasing engagement

19-20 Nov | Free registration | Earn up to 12 CPD hours!
https://eu1.hubs.ly/H0mGBN-0

This conference was developed by the PCDO Society in conjunction with OmniaMed Communications. The sponsoring pharmaceutical, devices, training and educational companies have contributed financial support towards this event but have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible. A full list of confirmed sponsors for this event can be found by clicking this link. https://tinyurl.com/ywxdh6xm

28/08/2025

Acknowledging the scope of the NICE NG28 update, the Primary Care Diabetes and Obesity (PCDO) Society supports the proposal to move away from the current “one-size-fits-all” treatment plan for type 2 diabetes, with an emphasis on a more person-centred approach, focusing on the prevention of cardiovascular and renal complications.

Proposed changes will ensure earlier access to the newer therapies such as SGLT2 inhibitors and GLP-1 receptor agonists, in line with current evidence and international recommendations from the American Diabetes Association and the European Association for the Study of Diabetes. The PCDO Society advocates the adoption of early, evidence-based interventions in type 2 diabetes care to achieve optimal outcomes across the spectrum of co-morbidities.

It is vital that there is equity of access to such medications across the country and the PCDO Society commends the acknowledgement of under prescribing in certain groups, such as women, older people and Black people.

Any NICE guidance should consider the financial implications for Integrated Care Boards and workload considerations for primary care staff.

As a key stakeholder, the PCDO Society welcomes the opportunity to feedback on these proposals, with a view to shaping the guidance and ensuring the best possible care for people living with type 2 diabetes.

14/08/2025

Naresh Kanumilli meets Philip Newland-Jones, Consultant Pharmacist in Diabetes and Endocrinology, to discuss the discontinuation of Levemir (insulin detemir), and the joint guidance from the PCDO Society and Association of British Clinical Diabetologists.

Watch the interview at: https://eu1.hubs.ly/H0mn8_C0

Levemir, in both its Penfill and Flexpen presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.

In response to this, we have published guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.

View the guidance at: https://eu1.hubs.ly/H0mn5NJ0

14/08/2025

Levemir insulin, in both its Penfill and Flexpen presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.

In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.

View the guidance at: https://eu1.hubs.ly/H0mmJBd0

Address

London

Opening Hours

Monday	9am - 5:30pm
Tuesday	9am - 5:30pm
Wednesday	9am - 5:30pm
Thursday	9am - 5:30pm
Friday	9am - 5:30pm

Telephone

+442037358244

Website

https://pcdosociety.org/

Alerts

Be the first to know and let us send you an email when Primary Care Diabetes and Obesity Society posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Primary Care Diabetes and Obesity Society:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Featured

Help Mind Body
Pure Rheumatology London
1 Welbeck Street,

19/09/2025

18/09/2025

18/09/2025

17/09/2025

16/09/2025

15/09/2025

14/09/2025

12/09/2025

01/09/2025

28/08/2025

14/08/2025

14/08/2025

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Featured

Share